anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Use the lowest effective dose for the patient. The recommended initial dose is 5 mg for women and either 5 or 10 mg for men, taken only once per night immediately before bedtime with at least 7 to 8 hours remaining before the planned time of awakening. If the 5 mg dose is not effective, the dose can be increased to 10 mg. In some patients, the higher morning blood levels following use of the 10 mg dose increase the risk of next day impairment of driving and other activities that require full alertness [see Warnings and Precautions (5.1)]. The total dose of zolpidem tartrate tablets should not exceed 10 mg once daily immediately before bedtime. Zolpidem tartrate tablets should be taken as a single dose and should not be readministered during the same night. 

The recommended initial doses for women and men are different because zolpidem clearance is lower in women.
PURPOSE:A viral multiplication inhibitor, containing neplanocin C an active constituent and effective against humam T cell leukemic virus considered as the same kind as AIDS causative virus or Epstein-Barr virus which is a causative virus of Burkitt's lymphoma or epipharyngeal cancer. CONSTITUTION:A multiplication inhibitor for human T cell leukemic virus (hereinafter abbreviated to HTLV) or Epstein-Barr virus (hereinafter abbreviated to EBV) containing neplanocin C as an active constituent. The neplanocin C as an antimicrobial agent against plant pathogenic molds and carcinostatic agent is effective as a multiplication inhibitor for HTLV or EBV. The dose thereof is 50-200mg/day, preferably about 100mg/day for adults. Generally, the agent may be prepared as an injection is 5-10ml concentration aseptically prepared in distilled water for injection and intravenously injected. The agent may be prepared as a tablet or suppository.
Approximately 75% of all patients with colon carcinoma present at a stage when all gross tumor can be surgically resected. Despite that high resectability rate, about 50% of all colon adenocarcinoma patients die of subsequent metastatic disease not apparent at surgery. These individuals could benefit from adjuvant local or systemic chemotherapy.

Based on the encouraging antitumor activity of 5-FU plus leucovorin(LV) in patients with metastatic colon carcinoma6,7, several investigators reported their results using this combination in the adjuvant setting. Results of an NSABP C-038 suggested that postoperative 5-FU plus leucovorin reduces the risk of colon cancer recurrence by 30% and the associated mortality by 32% compared with MOF(semustine, vincristine, and 5-FU). Recently, investigators from the IMPACT group9 analyzed the role of adjuvant 5-FU plus high dose leucovorin given 5 days every 28 days for a total of six courses versus no treatment in patients with stage II or III colon cancer. The treatment arm showed a significant reduction (by 22%) in mortality (P=0.029) and a 35% reduction in relapse rate (P=0.0001). Preliminary results from other studies have also suggested benefits of 5-FU plus leucovorin as adjuvant treatment of colon cancer10,11,12. Those studies had employed chemotherapy with 5-FU plus leucovorin, although there were differences in duration of treatment and drug dose among those trials, it is striking that all revealed a similar magnitude of benefit for adjuvant chemotherapy with 5-FU and leucovorin in node positive patients. At the present time, both 5-FU plus levamisole and 5-FU plus leucovorin can be considered acceptable adjuvant chemotherapy regimens for patients with node positive disease.

Thymidylate synthase(TS) is a critical therapeutic target for the fluoropyrimidine cytotoxic drugs that are the mainstay of the treatment for patients with advanced colorectal cancer. TS provide the sole de nono source of thymidylate for DNA synthesis. The clinical importance of TS in determining fluoropyrimidine cytotoxicity has been established in both clinical and preclinical study. Increased expression of TS protein due to underlying gene amplification has been described in cell lines selected for drug resistance by exposure to 5-FU.22,23 Several investigators have also demonstrated that intratumoral TS activity are predictive for response to 5-FU.24-26 High TS activity was associated with no response, whereas a low TS activity was associated with good response to 5-FU.
This study tests whether a single session of exposure therapy may be enhanced by the addition of one of two augmentation strategies, including engagement in anti-phobic actions and fading of safety behaviors. Because utilization of safety behaviors is functionally precluded by anti-phobic action, the present study design will both replicate and extend prior research by addressing whether anti-phobic actions enhance exposure therapy beyond the mere fading of safety behaviors. A total of 100 individuals between the ages of 18 and 65 meeting DSM-IV criteria for acrophobia (fear of heights) will be randomly assigned to one of four conditions including (1) standard exposure therapy, (2) exposure therapy with safety behavior fading, (3) exposure therapy with safety behavior fading and anti-phobic actions, and (4) a wait-list control condition. All participants will complete an online prescreen and face-to-face screening assessment to determine eligibility and pre-treatment symptom severity. Participants will also complete assessments at post-treatment and 1-month follow-up assessments. Subjective fear during two behavioral approach tests (in the treatment and generalization context, respectively) conducted at pre-treatment, post-treatment, and 1-month follow-up assessments will serve as the primary measure of treatment outcome. Additionally, a battery of self-report questionnaires will be completed at pre-treatment, during treatment, at post-treatment, and at a 1-month follow-up assessment.
Patients will be selected from Rh isoimmunized patients (positive titre of indirect coomb's test) who are scheduled to have intrauterine blood transfusion. This intrauterine blood transfusion is due to fetal anemia, and it is detected when the measurement of PSV (peak systolic velocity) of middle cerebral artery is more than 1.5 MoM (multiple of the median) according to Fetal Medicine unit of Cairo University protocol. All fetuses are free of structural and functional Fetal and echocardiographic anomaly scan.
PURPOSE: A recombinant adenovirus containing trans-splicing ribozyme and a cancer therapeutic gene is provided to effectively prevent and treat cancer. CONSTITUTION: A recombinant adenovirus contains trans-splicing ribozyme which acts to a cancer-specific gene and a cancer therapeutic gene. The cancer-specific gene is TERT(Telomerase Reverse Transcriptase) mRNA(sequence number 1). The trans-splicing ribozyme is Ri67 ribozyme(sequence number 2). The cancer therapeutic gene is HSVtk(Human Simplex Virus thymidine kinase, sequence number 3) and sPD-1(soluble Programmed Death-1, sequence number 4). A pharmaceutical composition for preventing or treating cancer contains the recombinant adenovirus as an active ingredient. The composition additionally contains a pharmaceutically acceptable carrier, excipient, or diluent.
Pancreatic adenocarcinoma (PDAC) represents the fourth leading cause of cancer-related mortality in the United States, with an estimated 39,950 deaths attributable to PDAC in 2014 (http://seer.cancer.gov/statfacts/html/pancreas.html). Over 90% of patients have inoperable disease at presentation, at which point systemic therapy becomes the primary form of treatment.

Treating PDAC has been challenging and few approved drugs are available. Recently, however, some breakthroughs have occurred, raising hope that this aggressive disease can be better controlled. FOLFIRINOX, a combination of 5FU, oxaliplatin, and irinotecan, has been found to be substantially superior to treatment of gemcitabine alone in patients with metastatic disease and good performance status. Similarly, gemcitabine and nab-paclitaxel, a regimen with less non-hematologic toxicity, demonstrated improved overall survival and progression-free survival compared to gemcitabine alone. Both of these combinations or modifications of these combinations are now front line options for patients with good performance status. Furthermore, these improvements in survival, however incremental, now afford patients with pancreatic cancer time to participate in and possibly benefit from clinical trials of novel therapeutics.
Non-myeloablative bone marrow transplant with fludarabine, cyclophosphamide, total body irradiation conditioning regimen and cyclophosphamide, mycophenolate mofetil, and tacrolimus prophylaxis for graft-versus-host disease (GVHD). Tacrolimus was given for 60 days.
Two-year carcinogenicity studies in B6C3F1 mice and Wistar rats were conducted to assess the carcinogenic potential of ciclesonide. Ciclesonide demonstrated no tumorigenic potential in a study with mice that received oral doses up to 900 mcg/kg/day (approximately 7 times the MRHDOID in adults and pediatric patients ≥ 12 years of age on a mcg/m2 basis) and a study with rats that received inhalation doses up to 193 mcg/kg/day (approximately 3 times the MRHDOID in adults and pediatric patients ≥ 12 years of age on a mcg/m2 basis).

Ciclesonide was not mutagenic in an Ames test or in the Chinese hamster lung V79 cell/hypoxanthine-guanine phosphoribosyl transferase (HGPRT) forward mutation assay and was not clastogenic in a human lymphocyte chromosomal aberration assay or in an in vitro micronucleus test. However, ciclesonide was clastogenic in an in vivo mouse micronucleus test. The concurrent reference corticosteroid (dexamethasone) in this study showed similar findings.

Fertility and reproductive performance were unaffected in male and female rats dosed by the oral route up to 900 mcg/kg/day (approximately 15 times the MRHDOID in adults based on mcg/m2).
Sporadic studies have reported the occurrence of nasopalatine duct cysts after maxillary anterior implant surgery, and the treatment methods still have clinical uncertainty. We report a potential therapy method that successfully treated a nasopalatine duct cyst that developed and expanded 1 year after maxillary anterior implant placement following periodontally hopeless teeth extraction. The nasopalatine cyst was treated surgically without removing implants. During flap surgery, the cyst was removed intact, and the exposed implant's surface was debrided thoroughly by hydrogen peroxide (H2O2) rinsing, glycine air polishing, and saline rinsing. To deal with the significant bone defect caused by the cyst, a bovine porous bone mineral injected platelet-rich fibrin (BPBM-i-PRF) complex was applied to fill the defect, following a resorbable collagen membrane to cover. Seven years after surgery, no cyst recurrence was observed, and bone regeneration in the bone graft area was stable. The implants functioned well without mobility. For nasopalatine duct cysts associated with dental implant placement, complete surgical debridement and longitudinal stable bone regeneration are possibly accessible by regenerative surgery without implant removal.
A device for controlled release of an active substance through one or more asymmetric membranes by diffusion and/or osmotic pumping.  The active substance may typically be a pharmaceutically active substance such as antihypertensive and antianxiety agent to be released into the fluid of the gastro-intestinal tract of an animal over a prolonged period of time.          The asymmetric membranes may be permeable and made of for example a cellulose ester or ethyl cellulose.  The active substance may be released by osmotic pumping or by diffusion.          Also disclosed is a process for producing the device by a phase inversion process.  The asymmetric membrane is comprised of two membrane layers, one being a relatively thick and very porous substructure and the other being a very dense thin skin.
PURPOSE: Medication related osteonecrosis of the jaw (MRONJ) is a risk for patients taking anti-resorptive or anti-angiogenic medications. The American Association of Oral and Maxillofacial Surgeons (AAMOS) has classified MRONJ in stages to reflect the severity of the disease and allows implementation of suitable treatment pathways. MRONJ risk is < 5% in cancer patients and < 0.05% in osteoporosis patients. Management is subdivided into operative and non-operative, with advances in the literature investigating adjuvants. Leukocyte-Platelet Rich Fibrin (L-PRF) is an autologous biomaterial consisting of leukocytes and platelets embedded within a fibrin matrix with the ability to release growth factors enabling angiogenesis, bone regeneration and soft tissue healing. This paper's aim is to investigate the effects of L-PRF in conjuction with surgical debridement for management of MRONJ.
METHODS: Twenty-two cases with established MRONJ were treated with either surgical intervention (Group A) or with surgical intervention and L-PRF (Group B), from 2016 to 2023 at Edinburgh Dental Institute (EDI). Treatments were deemed successful when the patients were asymptomatic, displayed complete soft tissue healing with the absence of infection/inflammation, fistula, or exposed bone.
RESULTS: All cases in Group B had healed in contrast to 54.5% not healed in Group A; p value < 0.05 indicating statistical significance.
CONCLUSION: The use of L-PRF as an adjuvant to surgical management of MRONJ is promising with its favourable functional capacity, simple application, and success of treatment outcomes.
The present invention provides a human DNA sequence for the FMR2 gene, which is associated with FRAXE-associated mental retardation, and provides a source for suitable probes for diagnosis and source of suitable sequences for developing antibodies to the protein (FMR2P) as the basis for development of an immunocytochemical test for the presence of FMR2P protein, and also DNA sequences useful for deriving the protein sequence (FMR2P) for possible therapy. The isolation and characterization of the FMR2 gene thus permits an improvement in diagnostic techniques, as well as the possiblity for genetic manipulation to overcome FRAXE-associated mental retardation. In one aspect, the invention is directed to an isolated and purified DNA sequence of at least 9.5 kb, which encodes a putative 1301 amino acid protein. In particular, the invention relates to the FMR2-coding DNA sequence as shown in the figure, from position 394 in the DNA sequence and position 1 in the protein sequence (ATG codon) to position 4296 in the DNA sequence and position 1301 in the protein sequence (TTG codon), and functionally equivalent DNA sequences. The invention also relates to variants of these sequences, having deletions, insertions or base substitutions which affect transcription and/or translation of the complete FMR2 gene. In still another aspect, the invention is directed to DNA probes which are hybridisable with such sequences to thereby detect abnormalities such as deletions, insertions and base substitutions (other than the CCG expansion).
The current study aims to compare the efficacy of blue light, bright light and dim light in the treatment of with nonseasonal major depression disorder(MDD) in adults. 162 patients with nonseasonal MDD will be randomized into three groups (i.e. blue light, bright light or dim light). The treatment will be performed five times a week for the first two weeks. And for the next 2 weeks, the treatment for patients will be undertook three times a week. There will be 16 times in total. The investigators will assess nonseasonal MDD'symptom severity in the baseline, 1 week,2 week, 4 week,6 week and 8 week. Through the study, 17-item Hamilton Depression Rating Scale (HAMD17),14-item Hamilton Anxiety Rating Scale (HAMA14),Quick Inventory of Depressive Symptoms, Self-Rated version (QIDS-SR)，Pittsburgh sleep quality index (PSQI) , Clinical Global Impression scale(CGI), Quality of Life, Enjoyment and Satisfaction Questionnaire (Q-LES-Q),Morningness-Eveningness Questionnaire (MEQ),Repeatable Battery for the Assessment of Neuropsychological Status(RBANS),subjective fatigue symptom scale and semantic differential scale will be obtained. The patients will also get individual's data of heart rate and blood pressure.
Patients receive pazopanib hydrochloride PO QD for 12-20 days in the absence of disease progression or unacceptable toxicity. Patients then undergo surgical resection of tumor between days 13 and 21 (24 hours after completion of pazopanib hydrochloride).
PURPOSE:A memory improver that contains a dipeptide, thus showing low toxicity and no side-effects. CONSTITUTION:The objective memory improver contains a dipeptide of the formula: H-X-Y-OH (H and Y are Tyr, Arg, where X differs from Y). It is effective not only in intracerebral administration but also in peripheral one. The dose is 1-500mg/day/man. It is prepared into injection solution, capsules, tablets, dust, granules, syrup or spray. Usually, it is given by injection, orally or in the form of suppository.
HCHF+ integrates healthful eating and physical activity with parenting education (parent role modeling and child feeding practices) and was recently shown to improve parent and child nutrition behaviors for participants in the Expanded Food and Nutrition Education (EFNEP) program. OrganWise Guys (OWG) will be used for children in first and second grades (ages 6-8). Choose Health: Food, Fun and Fitness (CHFF), developed by Cornell University, will be used for children in grades three through five (ages 8-10). HCHF+ includes 9 sessions to be delivered weekly.
Intervention Group Afterwards, patients taking paclitaxel-paclitaxel-herceptin will be given a nurse-led Motivational Interview about CIPN, physical activity and regular physical activity-walking. Patients will be instructed that the goal is to beat the previous number of steps each time. If he/she has problems/shortness of breath, chest pain, palpitation complaints during walking, he/she will be told to take a break from walking and rest. The study will be conducted under the supervision of a Medical Oncology specialist throughout the study, as well as the controls of patients with ongoing symptoms. Participants will be given a pedometer for regular follow-up, its use will be explained, and it will be told to mark it on the walking tracking chart. It will be emphasized that rhythmic walking is important for the pedometer to count correctly. Motivational Interview sessions will be conducted face-to-face at the beginning, week 4 and week 8.
Nitroglycerin is 1,2,3-propanetriol trinitrate, an organic nitrate whose structural formula is:

and whose molecular weight is 227.09. The organic nitrates are vasodilators, active on both arteries and veins.

The Nitroglycerin Transdermal System is a flat unit designed to provide continuous controlled release of nitroglycerin through intact skin. The rate of release of nitroglycerin is linearly dependent upon the area of the applied system; each cm2 of applied system delivers approximately .02 mg of nitroglycerin per hour. Thus, the 10 cm2 and 18 cm2 systems deliver approximately 0.2 and 0.4 mg of nitroglycerin per hour, respectively. Each 10 cm2 and 18 cm2 system contains 20.8 and 37.4 mg of nitroglycerin, respectively.

The remainder of the nitroglycerin in each system serves as a reservoir and is not delivered in normal use. After 12 hours, for example, each system has delivered approximately 12% of its original content of nitroglycerin.

The Nitroglycerin Transdermal System comprises two layers. Proceeding from the visible surface toward the surface attached to the skin, these layers are 1) polypropylene foil backing layer that is impermeable to nitroglycerin and 2) nitroglycerin in an acrylic-based polymer adhesive with a cross-linking agent to provide a continuous source of active ingredient. Prior to use, a peelable protective liner is removed from the adhesive surface. Each unit is sealed in a paper foil-lined pouch.

Cross section of the system:
INTRODUCTION: Prior studies have indicated that the frequency of premature ventricular complexes (PVC) increases after catheter ablation for atrial fibrillation (AF). However, these studies have primarily focused on patients whose PVC burden increased rather than including the full spectrum of outcomes.
METHODS AND RESULTS: We performed a single-center retrospective cohort study of consecutive patients who underwent first-time AF ablation from 1/2018 to 12/2022 for paroxysmal or persistent AF and had both preablation and postablation rhythm monitoring within 6 months of the procedure. Patients were excluded if they had prior AF or PVC ablation or were prescribed a class I or III antiarrhythmic medication. Among 2945 patients who underwent AF ablation during the study period, 130 patients underwent first-time AF ablation and received both pre and post ambulatory monitoring. The median PVC burden before ablation was <1%. Most patients (63%) had no change in PVC burden after AF ablation compared with preablation, and patients who had an increase in PVC burden were offset by those with reductions in PVCs. A paired analysis pre- and post-AF ablation showed no significant change in PVC burden (p = .495).
CONCLUSION: Although an elevated PVC burden after AF ablation may be seen clinically, the majority of patients have no change in burden. Studies that suggest an increase in PVC burden after AF ablation may suffer from incomplete sample selection and thus omit the important effect of regression to the mean.
The history of corneal cross-linking (CXL) dates back to 2003 when some German scientists investigated possible treatments to harden the corneal structure to increase its resistance in ectatic corneal diseases. Nowadays, CXL is considered the most effective therapy in ectatic corneal diseases due to its proven efficacy in hardening the cornea, thus halting the development of the disease. Since 2003, CXL applications have dramatically expanded and have been implemented in several other areas such as infectious keratitis, corneal edema, and before performing keratoplasty for various purposes. Moreover, several irradiation patterns are being studied to correct refractive errors, taking into account the corneal refractive changes that occur after the procedure. Currently, scleral cross-linking is also being investigated as a potential therapy in cases of progressive myopia and glaucoma. In this article, we provide a comprehensive overview of the available applications of cross-linking in nonectatic ocular conditions and highlight the possible future indications of this procedure.
FIELD: medicine. SUBSTANCE: means is designed as cigarette filled with stuff like nicotineless or low nicotine contents tobacco impregnated with ammonium nitrate. The tobacco burning, the mentioned substance decomposes at 200-270 C with lower nitrogen oxide released, having euphoric activity. Entering smoker lungs and blood, the lower nitrogen oxide creates pleasure and euphoria that is of preference when compared to that caused by nicotine or alcohol consumption due to its harmless action and no threat to cause addiction consequences. EFFECT: replaced tobacco and alcohol consumption. 4 dwg
Healthy participants (n = 10). At that time, they were explained how they should eat the nutraceutical food (HIC1®), starting the next day and for five consecutive days. During those 5 days, a nurse made contact calls to verify that the participant took the corresponding dose for the day. After 5 days of ingesting the nutraceutical compound, a blood sample was taken again to quantify post-ingestion levels of ORAC units, amino acids, vitamin B12, vitamin D, phosphorus, magnesium, calcium, and the lipid profile.